SHANGHAI YIZHONG PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.98 CNY | -2.88% |
|
-5.33% | -43.17% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capitalization 1 | 4,748 | 10,043 | 10,130 |
| Enterprise Value (EV) 1 | 3,812 | 8,916 | 8,934 |
| P/E ratio | -898 x | 70.5 x | 62.7 x |
| Yield | - | 0.43% | 0.48% |
| Capitalization / Revenue | 1,164,504,425 x | 42,564,502 x | 28,118,297 x |
| EV / Revenue | 934,861,647 x | 37,785,048 x | 24,797,989 x |
| EV / EBITDA | -187 x | 76.9 x | 53.4 x |
| EV / FCF | -75.2 x | 264 x | 162 x |
| FCF Yield | -1.33% | 0.38% | 0.62% |
| Price to Book | 4.04 x | 7.61 x | 6.92 x |
| Nbr of stocks (in thousands) | 205,760 | 205,760 | 205,760 |
| Reference price 2 | 23.08 | 48.81 | 49.23 |
| Announcement Date | 3/30/22 | 2/28/23 | 4/7/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | 4.078 | 236 | 360.3 |
| EBITDA 1 | -16.39 | -318.1 | -23.86 | -20.4 | 115.9 | 167.4 |
| EBIT 1 | -20.93 | -323.1 | -30.03 | -26.99 | 109.5 | 159.6 |
| Operating Margin | - | - | - | -661.96% | 46.4% | 44.29% |
| Earnings before Tax (EBT) 1 | -12.59 | -315.2 | -21.85 | -9.281 | 149.6 | 186.9 |
| Net income 1 | -12.59 | -315.2 | -21.85 | -3.997 | 142.9 | 161.6 |
| Net margin | - | - | - | -98.03% | 60.54% | 44.84% |
| EPS 2 | -0.0926 | -2.257 | -0.1440 | -0.0257 | 0.6923 | 0.7846 |
| Free Cash Flow 1 | -11.51 | 43.19 | -15.38 | -50.68 | 33.72 | 55.22 |
| FCF margin | - | - | - | -1,242.96% | 14.29% | 15.33% |
| FCF Conversion (EBITDA) | - | - | - | - | 29.09% | 32.98% |
| FCF Conversion (Net income) | - | - | - | - | 23.61% | 34.18% |
| Dividend per Share | - | - | - | - | 0.2098 | 0.2385 |
| Announcement Date | 7/2/21 | 7/2/21 | 7/2/21 | 3/30/22 | 2/28/23 | 4/7/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 163 | 131 | 47.6 | 936 | 1,128 | 1,196 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -11.5 | 43.2 | -15.4 | -50.7 | 33.7 | 55.2 |
| ROE (net income / shareholders' equity) | -6.14% | -132% | -8.59% | -0.56% | 11.5% | 11.6% |
| ROA (Net income/ Total Assets) | -5.9% | -79.7% | -7% | -2.31% | 5.36% | 6.81% |
| Assets 1 | 213.2 | 395.7 | 312.3 | 172.9 | 2,667 | 2,372 |
| Book Value Per Share 2 | 1.560 | 1.720 | 1.580 | 5.710 | 6.410 | 7.120 |
| Cash Flow per Share 2 | 0.0200 | 0 | 0 | 0.5400 | 3.450 | 4.450 |
| Capex 1 | 3.46 | 47.6 | 5 | 3.14 | 35.9 | 8.78 |
| Capex / Sales | - | - | - | 77.08% | 15.21% | 2.44% |
| Announcement Date | 7/2/21 | 7/2/21 | 7/2/21 | 3/30/22 | 2/28/23 | 4/7/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -43.17% | 819M | |
| +14.92% | 78.65B | |
| +9.32% | 8.94B | |
| -10.76% | 5.16B | |
| +54.31% | 4.85B | |
| +11.19% | 4.19B | |
| -22.37% | 2.32B | |
| +11.56% | 2.29B | |
| -32.35% | 2.19B | |
| +21.04% | 2.19B |
- Stock Market
- Equities
- 688091 Stock
- Financials Shanghai Yizhong Pharmaceutical Co., Ltd.